Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06434363
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2024-05-23
Brief Title:
Phase III Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Organization Data
Organization:
MD Anderson Cancer Center
Class:
OTHER
Study ID:
2024-0208
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
MD Anderson Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None